Aldeyra Therandshy;aandshy;peuandshy;tics Revenue and Competitors
Estimated Revenue & Valuation
- Aldeyra Therandshy;aandshy;peuandshy;tics's estimated annual revenue is currently $3.6M per year.
- Aldeyra Therandshy;aandshy;peuandshy;tics's estimated revenue per employee is $155,000
Employee Data
- Aldeyra Therandshy;aandshy;peuandshy;tics has 23 Employees.
- Aldeyra Therandshy;aandshy;peuandshy;tics grew their employee count by -12% last year.
Aldeyra Therandshy;aandshy;peuandshy;tics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Finance, Interim CFO, and Treasurer | Reveal Email/Phone |
3 | VP, Commercial Strategy and Operations | Reveal Email/Phone |
4 | VP, Quality Assurance | Reveal Email/Phone |
5 | Senior Director, CMC | Reveal Email/Phone |
6 | Chief Development Officer | Reveal Email/Phone |
7 | Associate Director Clinical Operations | Reveal Email/Phone |
8 | Chief Financial Officer | Reveal Email/Phone |
9 | Operations Manager | Reveal Email/Phone |
Aldeyra Therandshy;aandshy;peuandshy;tics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Aldeyra Therandshy;aandshy;peuandshy;tics?
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.
keywords:N/A
N/A
Total Funding
23
Number of Employees
$3.6M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aldeyra Therandshy;aandshy;peuandshy;tics News
MDA levels are elevated in the tears of patients with dry eye disease. Reproxalap (Aldeyra Therapeutics) is a first-in-class novel RASP...
Other Companies in Lexington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.6M | 23 | 28% | N/A |
#2 | $1.7M | 23 | 10% | N/A |
#3 | $2.3M | 23 | 5% | N/A |
#4 | $3.7M | 23 | 0% | N/A |
#5 | $5.2M | 23 | -12% | N/A |